A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease.

Trial Profile

A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Salbutamol/ipratropium bromide (Primary) ; Ipratropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2012 Official title amended as reported by European Clinical Trials Database.
    • 19 Feb 2010 Results were reported in Respiratory Medicine.
    • 02 Jun 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top